Vivoryon Therapeutics AG AI Stock Analysis
Want to see NL:VVY full AI Analyst Report?
Vivoryon Therapeutics AG (VVY) AI Stock Analysis
Vivoryon Therapeutics AG
(Amsterdam:VVY)
The overall score is heavily pressured by the company's pre-revenue status and ongoing cash burn, despite improved cost controls. Technicals confirm a sustained downtrend, and the negative P/E offers no valuation support. The primary risk remains the need for future dilutive financing.
Vivoryon Therapeutics AG (VVY) vs. iShares MSCI Netherlands ETF (EWN)
- Market Cap
- EUR 19.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 58.24K
- Price to Earnings (P/E)
- -3.1
- Beta (1Y)
- 0.56
- Revenue Growth
- ―
- EPS Growth
- 51.44%
- Country
- Netherlands
- Employees
- 13
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Vivoryon Therapeutics AG Business Overview & Revenue Model
Company Description
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and pr...
Vivoryon Therapeutics AG Earnings Call Summary
The earnings call highlighted significant clinical and financial progress, particularly in reducing expenses and advancing the varoglutamstat program, while also addressing challenges such as a reduced cash position and the need for additional financing for future studies.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
In the recent call discussing Vivoryon's first half 2025 results, several key metrics and achievements were highlighted. Research and development expenses for the period were EUR 2.8 million, a significant reduction from EUR 10.3 million in the first half of 2024, primarily due to decreased clinical development costs and production expenses. General and administrative expenses also saw a decline to EUR 2.8 million from EUR 3.5 million in the previous year. Consequently, the net loss for the first half of 2025 was reduced to EUR 5.5 million, compared to EUR 13.6 million in the same period of 2024. The company reported holding EUR 4.8 million in cash and cash equivalents as of June 30, 2025, with a cash runway extending into January 2026, excluding funds from a standby equity purchase agreement. Vivoryon also secured U.S. patents for varoglutamstat, ensuring market exclusivity through 2044. The company presented compelling kidney function data from its Phase II studies at the European Renal Association Annual Congress, showcasing statistically significant improvements in kidney function with varoglutamstat compared to placebo. Preparations for a dedicated Phase IIb study in diabetic kidney disease are underway, highlighting Vivoryon's strategic focus on expanding its therapeutic impact in the kidney disease market.
Vivoryon Therapeutics AG Financial Statement Overview
Summary
Pre-revenue biotech with persistent net losses and negative cash flows, though the burn rate has improved significantly. Minimal debt provides some stability, but thin equity and the need for future capital raises weigh heavily on the score.
Income Statement
20Very NegativeBalance Sheet
30NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | -3.62M | 0 | 10.76M |
| Gross Profit | -141.00K | -147.00K | -147.00K | -3.10M | -161.00K | 9.03M |
| EBITDA | -6.90M | -9.03M | -20.34M | -28.35M | -28.17M | -12.03M |
| Net Income | -6.77M | -8.85M | -20.57M | -28.34M | -28.16M | -12.65M |
Balance Sheet | ||||||
| Total Assets | 4.17M | 7.52M | 11.28M | 30.83M | 31.38M | 24.52M |
| Cash, Cash Equivalents and Short-Term Investments | 2.45M | 5.62M | 9.37M | 28.58M | 26.55M | 14.66M |
| Total Debt | 76.00K | 108.00K | 102.00K | 38.00K | 132.00K | 224.00K |
| Total Liabilities | 2.60M | 2.79M | 3.40M | 4.55M | 4.87M | 7.96M |
| Stockholders Equity | 1.56M | 4.73M | 7.88M | 26.28M | 26.51M | 16.56M |
Cash Flow | ||||||
| Free Cash Flow | -7.11M | -8.46M | -19.18M | -22.05M | -21.81M | -11.29M |
| Operating Cash Flow | -7.10M | -8.46M | -19.17M | -21.54M | -21.79M | -11.26M |
| Investing Cash Flow | 2,000 | -6,000 | 10.00M | -10.51M | -13.00K | -28.00K |
| Financing Cash Flow | 4.71M | 4.71M | -57.00K | 24.16M | 33.38M | -827.00K |
Vivoryon Therapeutics AG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:VVY, the sentiment is Negative. The current price of 0.71 is below the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.95, and below the 200-day MA of 1.18, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 39.77 is Neutral, neither overbought nor oversold. The STOCH value of 56.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NL:VVY.
Vivoryon Therapeutics AG Peers Comparison
Overall Rating
NL:LKFT74Outperform
NL:PHARM73Outperform
NL:CRBN68Neutral
NL:DSFIR62Neutral
NL:AVTX41Neutral
NL:VVY40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | EUR 2.07B | 4.26 | 16.88% | ― | 223.08% | ― | |
| 73Outperform | EUR 793.78M | 35.07 | 8.96% | ― | 1.73% | ― | |
| 68Neutral | EUR 1.51B | 24.31 | 8.30% | 3.81% | -3.37% | -8.22% | |
| 62Neutral | EUR 24.81B | -21.49 | ― | 2.41% | -44.75% | -301.20% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 41Neutral | EUR 101.15M | -1.14 | -25.04% | ― | -32.85% | 26.72% | |
| 40Underperform | EUR 21.03M | -3.09 | -215.13% | ― | ― | 51.44% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NL:VVY | Vivoryon Therapeutics AG | 0.71 | -0.92 | -56.33% | |
| NL:PHARM | Pharming Group N.V. | 1.12 | -0.27 | -19.29% | |
| NL:AVTX | Avantium N.V. | 1.70 | -2.45 | -58.93% | |
| NL:CRBN | Corbion NV | 26.26 | 8.60 | 48.72% | |
| NL:LKFT | Lakefront Biotherapeutics Nv | 31.46 | 4.98 | 18.81% | |
| NL:DSFIR | DSM-Firmenich AG | 103.60 | 36.59 | 54.60% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026
